Introduction
Infection remains a leading cause of morbidity and mortality in patients with chemotherapy-induced neutropenia. The prompt initiation of broad-spectrum antibacterial therapy for the febrile, neutropenic patient has had a profound effect in reducing mortality from gram-negative infections, and is presently considered standard of care. 1 Several antibiotic regimens have proven efficacy in the setting of neutropenic fever. Traditionally, combining antipseudomonal penicillin with an aminoglycoside has been employed, but excellent results have also been reported with the use of monotherapy with antibiotics such as ceftazidime, imipenem-cilastatin, cefepime and piperacillin-tazobactam. [2] [3] [4] Patients undergoing chemotherapy for acute leukemia or hematopoietic cell transplantation face a prolonged (2-4 week) period of neutropenia. Because of the breakdown of the normal mucosal barrier resulting from treatment, the prevalent use of steroids, and the necessity for indwelling catheters, these patients are at very high risk for developing fever and infection. Despite many recent advances in antimicrobial therapy, the emergence of resistant organisms can be devastating to neutropenic and immunocompromised patients. The growing problem of bacterial resistance is usually first encountered in hospital areas where broadspectrum antibiotic use is common and frequently empirical, such as transplantation and intensive care units. Several methods have been proposed to decrease the emergence of resistant organisms, including optimizing antibiotic use, restricting antibiotic classes, using combination therapy, and antibiotic cycling. 5 Of these methods, antimicrobial cycling has been less extensively studied.
We undertook a prospective cohort trial within a hematologic malignancy and hematopoietic cell transplant unit, evaluating the use of prophylactic levofloxacin during neutropenia combined with cycling of the antibiotic regimen used for empiric treatment of neutropenic fever. The primary end point of the study was to determine if there was a difference in resistance patterns of isolated bacteria. Secondary end points were to determine a difference in the incidence of Clostridium difficile colitis, changes in vancomycin use, and changes in mortality between the prospective trial and the retrospective cohort.
Methods
The blood and marrow transplantation unit (BMTU) at West Virginia University Hospitals (WVUH) consists of 12 private, high-efficiency particulate arrestance filtered inpatient rooms designed for patients undergoing hematopoietic cell transplantation and treatment for aggressive hematologic malignancies. A change in management protocol regarding antibacterial prophylaxis and empiric therapy was driven by the occurrence of a cluster of early deaths in patients with febrile neutropenia. Compliance with the treatment protocol was ensured by the presence of dedicated pharmacists and physicians assisting with antimicrobial therapy selection. Permission for the study was obtained from the West Virginia University Institutional Review Board. The study period was from January 1999 to December 2004, and consisted of a before (January 1999-February 2002) and after (March 2002-December 2004) intervention period. Infection control measures, including hand-washing policies and isolation procedures, remained constant throughout the study period.
From January 1999 through February 2002, standard of care in the BMTU did not involve the use of routine prophylactic antibiotics in patients who were neutropenic (defined as absolute neutrophil count (ANC)p500 cells/ml). Empiric antibiotics were started (piperacillin and gentamicin) at initial neutropenic fever (ANCp500 cells/ml and temperature X38.31C). Beginning March 2002, prophylaxis with levofloxacin was given to all patients in whom the duration of neutropenia was expected to be longer than 10 days. Empiric antibiotics for the initial neutropenic fever were chosen according to a rotating 8-month schedule: imipenem-cilastatin monotherapy, cefepime with extendedinterval tobramycin and piperacillin-tazobactam with extended-interval tobramycin (see Figure 1 ). Antibiotics were continued until neutrophil recovery and/or infection resolved. Prophylactic acyclovir and fluconazole were used throughout both treatment periods.
Standard dosages of antibiotics were used and adjusted for organ dysfunction if necessary (usual doses were levofloxacin 500 mg p.o. daily, cefepime 2 g i.v. every 8 h, imipenem-cilastatin 500 mg i.v. every 6 h and piperacillintazobactam 3000/375 mg i.v. every 6 h). Extended interval tobramycin dose was 5 mg/kg i.v. every 24 h, and adjusted for renal function. 6 Substitutions of antibiotic regimens were permitted for patient allergy or intolerance to the planned regimen. Vancomycin was added empirically to patients when fever and neutropenia persisted for more than 72 h or sooner if clinically indicated. If blood cultures were positive or a source of fever found, antimicrobial treatment could be tailored at the discretion of the medical team.
Positive blood cultures and episodes of C. difficileassociated diarrhea were identified by a retrospective inquiry of the microbiology laboratory database. Coagulase-negative staphylococcus was excluded from this analysis in order to ensure contaminated specimens were not included (there were 53 positive blood cultures for coagulase-negative staphylococcus in each time period). Rate of bacteremia was calculated as the number of positive cultures in the time period divided by the number of patient days, allowing for standardization between the two time periods. Sensitivity and resistance were determined by the break points standardized by the Clinical and Laboratory Standards Institute, formerly the National Committee for Clinical and Laboratory Standards. A resistant isolate was defined as resistance to any agents used in the study. As piperacillin/tazobactam was not routinely tested for resistance, a surrogate marker of piperacillin resistance was used. Multiple positive blood cultures of the same organism from the same patient were counted as one culture. Since October 2001, C. difficile toxin A and B was analyzed in stool by the C. difficile toxin A/B II assay (Wampole Laboratories, Princeton, NJ, USA). Before this time, only C. difficile toxin A was being detected. Records of antibiotic administration were obtained from the computerized pharmacy database at WVUH, and the defined daily dose (DDD) per 1000 patient days of each antibiotic was calculated according to previously described methods. 7 
Statistical analysis
Significance testing was carried out using Pearson w 2 test of homogeneity. Groups correspond to the two time periods while the various outcome measures, infection, mortality, etc. made up the other dimension. Significance levels were set at 0.05 and P-values were reported for all inferences.
Results
A total of 543 patients were admitted to the hematological malignancy and transplantation service during the study period. From January 1999 through February 2002 (before intervention), 217 patients were admitted with 7425 patient days during this period. After the initiation of the study (March 2002 through December 2004), 326 patients were admitted, accounting for 7716 patient days. Most patients were admitted on multiple episodes. As shown in Table 1 , the patient populations were different in the two periods. No patients with breast cancer underwent autologous transplantation after March 2002. There was an increase in the numbers of patients who underwent autologous transplantation for multiple myeloma after the initiation of Several streptococcus species isolated were resistant to quinolones after the start of prophylaxis and cycling (0.9 isolates/1000 patient days after vs none before, Po0.05).
The rate of streptococcus species resistant to penicillin was constant in both treatment periods (0.54 vs 0.52 cultures/ 1000 patient days) (Figure 3a ).
Resistance patterns: gram-negative organisms Figure 3b shows the decrease in the gram-negative bacteremia rate, without significant increases in resistance. Figure 2 Staphylococcus and Enterococcus resistance patterns before and after intervention. Differences in culture results before (white) and after (black) the protocol began. The increases in E. faecium and VRE were statistically significant. Enterobacteriaceae family. Within the Enterobacteriaceae family, there was no difference in resistance to quinolones, aminoglycosides or imipenem after starting prophylaxis and cycling. Resistance to piperacillin and ceftazidime was also similar in both time periods (Figure 3d ).
C. difficile-associated diarrhea
The rate of C. difficile-associated diarrhea showed a nonsignificant increase after the initiation of prophylactic and cycling antibiotics (3.1 vs 5.1 episodes/1000 patient days, P ¼ 0.07). The incidence of C. difficile was greatest during rotations incorporating imipenem, when 69% (27/39) of the episodes occurred.
Antibiotic use
With the prophylactic and rotating antibiotic scheme, the use of vancomycin decreased (397 vs 287 DDD/1000 patient days, Po0.05). As shown in Table 3 , the DDD per 1000 patient days of each antibiotic corresponded to the appropriate time in the scheduled rotation. Except for vancomycin, the antibiotic use data were not consistently available before July 2003.
Morbidity/mortality
There was no difference in infectious mortality or death during neutropenia between the two periods (Table 4) 
Discussion
Patients undergoing treatment for hematological malignancy and HSC transplant often have complications from infection, especially during neutropenia. When infections occur early in the course of treatment or are resistant to usual antibiotics, outcomes are compromised. There was a concern with early deaths from sepsis in patients with neutropenia in 2001 and early 2002. As a result, we initiated prophylactic antibiotics for patients undergoing treatment when prolonged neutropenia was expected and started empiric antibiotic therapy for neutropenic fever based on a rotating schedule. Prophylactic antibiotics during neutropenia have been extensively studied in the past. Meta-analysis has shown consistent decreases in gram-negative infections (bacteremia), with no reduction in mortality. 8, 9 A recent study suggested increased mortality in hematological malignancy patients upon discontinuation of levofloxacin prophylaxis. 10 The major concern in implementing prophylaxis is the occurrence of antibiotic resistance. Antibiotic cycling has been suggested as a method for decreasing or controlling resistance in microorganisms. In theory, the antibiotic agents undergo rotation in a given time period, alternating resistance pressure in the microbial environment. Bacteria with resistance to an agent would lose their growth advantage when the agent is withdrawn from use, and exposure to another class of antibiotics would eliminate these resistant organisms. Ideally, the agents selected for rotation should not share similar mechanisms of acquiring resistance. The appropriate length of cycle interval remains an area of speculation. [11] [12] [13] [14] A combination of these two approaches was used in order to prevent early deaths, while preserving the utility of our antibiotic arsenal.
The intervention has been effectively initiated on the BMT unit, with excellent compliance to the protocol obtained. This study shows that the use of prophylactic levofloxacin during neutropenia and rotating the empiric antibiotics used for treatment of neutropenic fever was associated with decreased rates of gram-negative bacteremia without significant increases in antibiotic resistance of these organisms. Overall use of vancomycin decreased after the start of the protocol, suggesting less persistent fever during neutropenia. Despite decreased vancomycin use, there was an increasing incidence of resistant gram-positive bacteremia (VRE). In addition, resistance to levofloxacin did develop in the streptococcal isolates. Gram-negative organisms did not develop resistance to the antibiotics cycled, although the number of isolates was small. Overall mortality and infection-related mortality rates did not increase, but more patients required ICU care after the start of the protocol. The equal mortality and infection rates are noteworthy findings considering the patients treated after initiation of the protocol underwent higher risk transplant procedures.
Prophylaxis may allow overpopulation of resistant organisms or other changes in the microbial flora.
Levofloxacin use has been associated with development of resistance and C. difficile-associated diarrhea. 10, 15, 16 Perhaps the implementation of quinolone prophylaxis accounts for some of the increased resistance, especially in the Enterococcus species, seen in our study. Agents with anaerobic activity may contribute to the development of VRE. [17] [18] [19] The emergence of VRE appeared to correlate with the imipenem arm of the cycling protocol.
At the start of the study, two major interventions were initiated -levofloxacin prophylaxis during neutropenia and antibiotic cycling of agents used for neutropenic fevermaking it difficult to distinguish the contributions of each to the results obtained. Other limitations in this analysis include the retrospective data collection, use of an historical control group instead of a randomized design, and changes that occurred in the baseline characteristics of the patient population. Owing to the methods of data collection, it was not possible to obtain data about antibiotic use for all of the antibiotics (except vancomycin) used in the cycling protocol before June 2003. The 8-month length of each cycle was chosen based on logistics as well as estimates that a cycle longer than 1 year may allow resistance to develop during the cycle, and a very short cycling protocol would be difficult to maintain.
Our data reinforce the need to continually monitor antibiotic use and resistance patterns in areas of high antibiotic pressure, such as hematological malignancy, BMT, and intensive care units. Future randomized controlled trials could help determine the utility of antibiotic cycling in decreasing the emergence of resistant bacteria.
